Strategy & Planning
Where direction is set. Execution sphere is programs/ + projects/.
Anchor document
Founder’s strategic vision lives in Brain → 5-Year Vision. MISHA Foundation strategy aligns to it but is operationally distinct.
Year 1 OKRs (working draft)
O1 — Legitimate, fundable foundation exists.
- KR1: HK CLG incorporated (Day 30)
- KR2: Holt SAB letter signed (Day 14)
- KR3: 1+ patron at $100k+ committed (Day 120)
- KR4: Public wiki live (Day 90)
- KR5: First grant disbursed (Day 180)
O2 — Patient registry has real records.
- KR1: RARE-X integration agreement signed (Month 6)
- KR2: 5+ STRC families enrolled (Month 9)
- KR3: IRB approval (Month 9)
O3 — Research output published openly.
- KR1: STRC hypothesis ranking + AlphaFold3 data on wiki (Month 6)
- KR2: 1 white paper published (Month 12)
Multi-year arc
| Year | Operating budget target | Headcount | Key milestone |
|---|---|---|---|
| 1 | $100k-300k | 1 (founder) | Incorporated, first patron, registry IRB, first grant |
| 2 | $500k-1.5M | 2-3 | Section 88 status, US fiscal sponsor active, 20+ registry families |
| 3 | $2M-5M | 4-6 | First larger grant from Croucher / HMRF, 100+ registry families, mouse-model data |
| 4 | $5M-15M | 8-12 | Asia-native lab beginning, China clinical-trial readiness work |
| 5 | $15M+ | 15+ | Direct lab operations, multi-target portfolio, FDA/NMPA pre-IND track |
Annual review cadence
Q4 each year: written annual review note in notes/{YYYY}-annual-review.md. Compare OKR delivery vs target. Inputs to next year’s OKRs.
Connections
[part-of]index[applies]Programs[applies]Fundraising[see-also]5-Year Vision[see-also]foundation-evolution-playbook